Ultrasound Test to Predict Portal Hypertension in Cirrhosis Without Biopsy
Tests an ultrasound liver scan to estimate portal hypertension in adults with cirrhosis.
Plain-language title generated from the registry record
Registry title: Noninvasive Prediction of Portal Hypertension in Cirrhosis Using Sound Touch Viscoelastography
Key facts
- Where
- Wenzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with liver cirrhosis who are planned to have a hepatic venous pressure gradient (HVPG) test. It checks whether a special ultrasound scan (STVi) can predict portal hypertension without surgery.
- Age
- Older than 18 years
- Sex
- All sexes can join
- Disease stage
- Clinically diagnosed liver cirrhosis. Portal hypertension is compared by HVPG of 10 mmHg or more versus under 10 mmHg.
- Earlier treatment
- People who had a TIPS procedure, or liver surgery with spleen removal, cannot join.
- Biomarker or test result
- Planned HVPG test. Cirrhosis is shown by tissue test, endoscopy, imaging or certain blood test results.
Main reasons for not taking part
- Had a TIPS procedure
- Had liver surgery with spleen removal
- Cancer of the liver
- Blood clot in the portal vein
- Severe heart, lung, liver or kidney problems
Read by machine on 12 November 2026.
Where in China
- The First Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaContact: Shihao Xu, doctor's degreeTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- First Affiliated Hospital of Wenzhou Medical University
- Trial code
- NCT06316869
- Record updated
- 16 September 2026
- Original description
The objective of this observational study is to investigate and validate the utility of the Sound Touch Viscoelastography(STVi) technique in patients with liver cirrhosis for noninvasive prediction of Portal hypertension (PH). The primary research questions it seeks to address are as follows:Read full original descriptionShow less
Clinical Study of Noninvasive Prediction of Portal Hypertension in Cirrhosis Based on Sound Touch Viscoelastography
The objective of this observational study is to investigate and validate the utility of the Sound Touch Viscoelastography(STVi) technique in patients with liver cirrhosis for noninvasive prediction of Portal hypertension (PH). The primary research questions it seeks to address are as follows:
* What is the correlation between the liver STVi index and Portal Venous Pressure Gradient (HVPG)? * Is STVi an available tool to non-invasively predict PH in patients with liver cirrhosis? And the effectiveness and practicality of STVi will be validated. * To establish a predictive model for Clinically Significant Portal Hypertension (CSPH) utilizing liver STVi index as the primary indicator.
The HVPG is considered as the gold standard in this study and STVi was employed to quantify the STVi index of the liver in patients with liver cirrhosis. Researchers will compare the two patients groups, HVPG≥10 mmHg and HVPG<10 mmHg, to see the usage of STVi in the noninvasive prediction of PH.
Inclusion: Age older than 18 years; Clinically diagnosed with cirrhosis. Meeting the diagnostic criteria of the 2019 edition of the "Cirrhosis Diagnosis and Treatment Guidelines": (1) Histology consistent with cirrhosis diagnosis; (2) Endoscopy shows esophageal gastric varices or ectopic varices, excluding non-cirrhotic portal hypertension; (3) Imaging examinations such as ultrasound, LSM, or CT suggest features of cirrhosis or portal hypertension: such as splenomegaly, portal vein ≥1.3 cm, LSM measurements meeting diagnostic thresholds for cirrhosis of different etiologies; (4) In the absence of histology, endoscopy, or imaging examinations, the following abnormal indicators suggest the presence of cirrhosis (must meet 2 of the 4 criteria): a. PLT <100×10\^9/L, with no other explanations; b. Serum ALB <35 g/L, excluding malnutrition or other causes such as renal disease; c. INR >1.3 or prolonged PT (discontinuation of thrombolytics or anticoagulants for >7 days); d. AST/PLT ratio index (APRI): Adult APRI score >2, with attention to the influence of hepatotoxic drugs and other factors on APRI; Planning to undergo HVPG testing and meeting the indications for HVPG testing in the "Chinese Expert Consensus on the Clinical Application of Hepatic Venous Pressure Gradient (2018 edition)" : (1) Assessing the efficacy of drug therapy for primary and secondary prevention of esophageal gastric variceal bleeding; (2) Predicting the risk of esophageal gastric variceal bleeding and guiding treatment plan selection; (3) Predicting the risk, degree of progression, and clinical prognosis of decompensated events in cirrhosis; (4) Evaluating the efficacy of related new drugs; (5) Evaluating the accuracy of related non-invasive techniques; (6) Diagnosis and differential diagnosis of portal hypertension types; Able to understand and voluntarily sign a written informed consent form.
Exclusion: Hepatic malignancy; Portal vein thrombosis; Individuals with severe cardiac, pulmonary, hepatic, or renal dysfunction; Post-TIPS procedure; Post-hepatectomy splenectomy; Pregnant and postpartum women.